αnk1.1 clone pk136

All experiments were conducted under a UK Home Office project license (PPL 30/2442 and 30/2969). WT C57BL/6 mice were purchased (Harlan), RAG1^−/− mice were bred in-house, IL-22^−/− mice were kindly provided by Jean-Christophe Renauld (Ludwig Institute, Brussels), and IL-22RA1 reporter mice were generated as described in the Supplemental Experimental Procedures. MCMV Smith strain (ATCC) was prepared in BALB/c salivary glands and purified over a sorbital gradient. Virus from homogenized organs and tissue culture supernatants were titered on 3T3 cells. Mice were infected intraperitoneally (i.p.) with 3 × 10⁴ pfu MCMV and weighed daily. Some mice were injected i.p. with 200 μg αNK1.1 (clone PK136, BioXCell) or IgG control on days −2, 0, and +2 p.i. For T cell depletion, mice were injected (i.p.) with 200 μg αCD4 antibody (100 μg clone YTS191, 100 μg clone YTS3) and 200 μg αCD8 antibody (100 μg clone YTS156, 100 μg clone YTS169, all in-house). Neutrophils were depleted with 100 μg αLy6G (clone 1A8, BioXCell); for TRAIL neutralization mice were administered 250 μg of αTRAIL (clone N2B2, Biolegend), and for IL-22 neutralization mice were administered i.v. 50 μg goat IgG (Chemicon) or αIL-22 (R&D Systems). Some mice were treated with 100 μg IgG or αCXCL1 (clone 124014, R&D Systems). All administrations were day 0 and, for 4-day experiments, 2 p.i.

Cellular subsets were depleted by administering 0.200 mg of depleting antibody by intraperitoneal injection on days 6, 8, 11 and 15 following tumour inoculation. For CD8 T-cell depletion, αCD8a (clone 2.43, rat IgG2b, BioXCell) was compared to an isotype control antibody (clone LTF-2, rat IgG2b, BioXCell). For NK cell depletion, αNK1.1 (clone PK136, rat IgG2a) was compared to an isotype control antibody (clone C1.18.4, rat IgG2a, BioXCell).